Bank Of New York Mellon Corp Applied Genetic Technologies Corp Transaction History

Bank Of New York Mellon Corp

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	BUY	$3.01 - $4.12 $57,494 - $78,696	19,101 Added 174.87%	30,024 $90,000
Q2 2021 Aug 11, 2021	SELL	$3.62 - $5.23 $294,953 - $426,135	-81,479 Reduced 88.18%	10,923 $42,000
Q1 2021 May 13, 2021	BUY	$3.94 - $8.19 $67,476 - $140,261	17,126 Added 22.75%	92,402 $468,000
Q4 2020 Feb 09, 2021	BUY	$3.99 - $5.7 $6,292 - $8,988	1,577 Added 2.14%	75,276 $307,000
Q3 2020 Nov 12, 2020	BUY	$4.38 - $6.43 $4,791 - $7,034	1,094 Added 1.51%	73,699 $358,000
Q2 2020 Aug 12, 2020	BUY	$3.0 - $6.9 $185,427 - $426,482	61,809 Added 572.52%	72,605 $402,000
Q1 2020 May 06, 2020	BUY	$2.36 - $9.86 $2 - $9	1 Added 0.01%	10,796 $35,000
Q1 2019 May 14, 2019	SELL	$2.62 - $4.44 $875 - $1,482	-334 Reduced 3.0%	10,795 $45,000
Q3 2018 Nov 09, 2018	SELL	$3.85 - $7.35 $59,948 - $114,446	-15,571 Reduced 58.32%	11,129 $0
Q2 2018 Aug 06, 2018	BUY	$3.7 - $5.65 $49,650 - $75,817	13,419 Added 101.04%	26,700 $99,000
Q1 2018 May 15, 2018	BUY	$3.65 - $5.2 $7,851 - $11,185	2,151 Added 19.33%	13,281 $51,000
Q4 2017 Feb 09, 2018	BUY	$3.4 - $4.15 $37,842 - $46,189	11,130	11,130 $40,000

Ticker AGTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,632,200
Description
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Pha...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.